Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

BFLY outpaces TEM with stronger upside, leaner valuation, and expanding global reach in AI-powered diagnostics.

AstraZeneca’s AI algorithms, developed based on biomarkers and diagnosis data points, have shown promise in broadening the ...

Tempus AI secured a landmark $200 million, three-year foundation model deal with pharmaceutical leaders AstraZeneca AZN and Pathos. This aims to improve the company’s AI capabilities and help ...

Additionally, Tempus AI secured a $200 million contract from an expanded partnership with AstraZeneca (NASDAQ:AZN) and the Pathos Foundation, expected to drive medium-term growth in its Data and ...

In April 2025, AstraZeneca, Tempus and Pathos AI made a multi-year agreement to develop a large-scale multimodal deep learning model to expedite the discovery of cancer treatments.

Additionally, Tempus AI secured a $200 million contract from an expanded partnership with AstraZeneca (NASDAQ:AZN) and the Pathos Foundation, expected to drive medium-term growth in its Data and ...

Aurora Innovation, BYD, and Tempus AI are just three of Lingotto Innovation’s holdings with explosive growth potential.